期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 131, 期 12, 页码 -出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI149095
关键词
-
资金
- NIH [5U19AI144306]
B cells play a key role in the development of SLE, producing pathogenic antibodies that enhance inflammation and damage tissues and cells. While multiple therapies targeting B cells have been successful in mouse models, only belimumab has been approved for SLE treatment in patients. Integrating previous clinical trial experience with new research on B cell mechanisms in specific patient groups is crucial for developing effective treatment strategies, particularly focusing on B cell differentiation into plasma cells.
B cells have a prominent role in the pathogenesis of systemic lupus erythematosus (SLE). They are mediators of inflammation through the production of pathogenic antibodies that augment inflammation and cause direct tissue and cell damage. Multiple therapeutic agents targeting B cells have been successfully used in mouse models of SLE; however, these preclinical studies have led to approval of only one new agent to treat patients with SLE: belimumab, a monoclonal antibody targeting B cell-activating factor (BAFF). Integrating the experience acquired from previous clinical trials with the knowledge generated by new studies about mechanisms of B cell contributions to SLE in specific groups of patients is critical to the development of new treatment strategies that will help to improve outcomes in patients with SLE. In particular, a sharper focus on B cell differentiation to plasma cells is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据